Citations for: Bouchard, P. Chlormadinone Acetate (CMA) in Oral Contraception - a New Opportunity. Eur. J. Contracept. Reprod. Heal. CARE 2005, 10 (1), 7–11.

Entry Type
Name
Value
Parent Entry
Pharmacology Data Field
Androgen Receptor Activity
Antagonist
Chlormadinone Acetate (API)
Pharmacology Data Field
Estrogen Receptor Activity
Antagonist
Chlormadinone Acetate (API)
Pharmacology Data Field
Glucocorticoid Receptor Activity
Agonist
Chlormadinone Acetate (API)
Pharmacology Data Field
Mineralocorticoid Receptor Activity
No activity
Chlormadinone Acetate (API)
Metabolites
3β-Hydroxychlormadinone Acetate
N/A
Metabolites
2α,3α-Dihydroxychlormadinone Acetate
N/A
Toxicology Data Field
Carcinogenicity
"Tests have failed to show an increased risk for the development of malign tumours in the livers of oral contraceptive users."
Chlormadinone Acetate (API)
Pharmacology Data Field
Elimination Half-Life (t1/2)
Around 34 h (Bouchard), 25 h (Terlinden) for single dose administration, 38 h for multiple dose administration.
Chlormadinone Acetate (API)
Pharmacology Data Field
Serum Protein Binding
96% bound to albumin, does not bind to SHBG or CBG.
Chlormadinone Acetate (API)
Pharmacology Data Field
Metabolism
Hepatic.
Chlormadinone Acetate (API)
Pharmacology Data Field
Excretion
45% in urine, 42% in feces.
Chlormadinone Acetate (API)
Pharmacology Data Field
Cmax
1.60 +/- 0.46 ng/ml (single dose)
2.21 +/- 0.60, 2.06 +/- 0.47 ng/ml (multiple dose)
Chlormadinone Acetate (API)
Pharmacology Data Field
Tmax
1.6 +/- 0.4 h (single dose)
1.6 +/- 0.5, 1.4 +/- 0.4 h (multiple dose)
Chlormadinone Acetate (API)
Pharmacology Data Field
AUC
14.40 +/- 4.39 ng*h/mL (single dose)
19.36 +/- 5.50, 15.90 +/- 3.34 ng*h/mL (multiple dose)
Chlormadinone Acetate (API)
Pharmacology Data Field
Enzyme Interactions
Does not block CYP system.
Chlormadinone Acetate (API)
Pharmacology Data Field
Transformation of Endometrium
1.5 to 2.0 mg/day
Chlormadinone Acetate (API)